Kalshi, a prominent online prediction market platform, revealed plans to expand its offerings to include wagering on clinical trial outcomes and regulatory decisions by the Food and Drug Administration. The company framed the initiative as a pilot program designed to increase visibility into drug development data that typically remains restricted to industry insiders.
The platform’s leadership argued that the pharmaceutical industry operates with significant information constraints, with trial data largely controlled by sponsoring companies. By creating public markets around these outcomes, Kalshi contended that traders would establish real-time probabilities reflecting available evidence rather than promotional messaging from trial sponsors. The initiative was announced in partnership with artificial intelligence company AppliedXL, and the company released a comprehensive white paper on prediction markets in drug development that included endorsements from healthcare industry figures.
The expansion comes as prediction market platforms have faced increased scrutiny regarding potential for market manipulation and insider trading. Recent regulatory actions included an investigation by the Department of Justice into a former congressional candidate accused of placing bets on his own political event attendance, and separate instances of candidates betting on race outcomes. Additionally, federal regulators disclosed that someone with close access to a sitting president had profited substantially from predictions about speeches.
Kalshi implemented safeguards including employment verification requirements designed to prevent insider trading, and stated it would only list contracts after clinical trial enrollment periods close. The company also recently paused plans to offer contracts on flight cancellations following concerns that such markets could incentivize deliberate airport disruptions.
The platform has grown significantly, reaching one billion dollars in trading volume earlier this year and maintaining approximately five million monthly active users. While Kalshi emphasizes it is not a gambling operation, research experts have raised concerns about addictive features inherent to prediction markets and the adequacy of current regulatory protections for users.